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other immune cells (“serotherapy” or “in vivo T cell deple-
tion”) to prevent graft-versus-host disease (GVHD) appears
beneﬁcial. For rabbit polyclonal “antieT cell globulin” (ATG),
ﬁve randomized and multiple nonrandomized studies have
shown that, in the setting of adult marrow or mobilized
blood stem cell transplantation using myeloablative condi-
tioning, ATG given with conditioning prevents GVHD
without compromising relapse incidence or survival [1]. This
leads to improved immunosuppression-free survival [2] and
improved quality of life [3-5]. This is true in spite of the fact
that ATG appears to increase viral infections, particularly
Epstein-Barr virus (EBV)e driven post-transplantation
lymphoproliferative disorder [1].
Alemtuzumab (humanized rat monoclonal antibody tar-
geting CD52) may reduce GVHD to a greater degree than ATG
[6,7]. The incidence of relapse has been reported to be not
higher with alemtuzumab than it is with ATG [6,7]. Viral
infections may occur more frequently with alemtuzumab
than with ATG [8], except for EBV post-transplantation
lymphoproliferative disorder, which may be more frequent
with ATG. However, whether alemtuzumab can be
substituted for ATG as GVHD prophylaxis is not known
because only a few studies comparing ATG with alemtuzu-
mab are available, and all are retrospective.
The study of Willemsen et al. [9] is a welcome addition to
the group of retrospective studies. It showed that, compared
withw10 mg/kg ATG (Thymoglobulin, Sanoﬁ, Paris, France),
w.8 mg/kg alemtuzumab resulted in a trend toward less
acute GVHD, as expected. Also as expected, adenoviral
reactivation was more frequent in the alemtuzumab group,
whereas EBV reactivation was more frequent in the ATG
group. Surprisingly, relapse incidence was higher in the
alemtuzumab group, which resulted in lower overall and
relapse-free survival. This could not be attributed to the
longer half-life of alemtuzumab (compared with ATG), as
when patients with short alemtuzumab exposure (low area
under the time-concentration curve) were compared with
patients with long ATG exposure, the relapse incidence and
survival were still signiﬁcantly worse in the short exposureDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.11.674.
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tive exposure to antibodies for both groups. It should not be
assumed that the increased relapse incidence and mortality
with alemtuzumab applies to adults, who are more prone to
develop GVHD than children (without serotherapy) and,
thus, could theoretically derive a greater beneﬁt (less GVHD-
associated mortality and morbidity) from alemtuzumab.
The strength of the study is in its mechanistic compo-
nentsdimmune reconstitution and pharmacokinetics.
Reconstitution of virtually all immune cell subsets (neutro-
phils, monocytes, total and memory/effector CD4 T cells, total
andmemory/effector CD8 T cells, and NK cells, but not B cells)
was delayed in the alemtuzumab group, compared with the
ATG group. Thiswas caused, at least in part, by the longer half-
life of alemtuzumab, as when the patients with short alem-
tuzumab exposure were compared with the patients with
long ATG exposure, the reconstitution of all the immune cell
subsets was similar. As expected, among both alemtuzumab-
and ATG-treated patients, T cell reconstitution was faster in
patientswith lower exposure to the antibody. Complete donor
chimerism (among mononuclear cells) was achieved faster in
the ATG group than in the alemtuzumab group, perhaps
because of the longer half-life of alemtuzumab.
The weakness of the study is in the patient population
studied, ie, pediatric patients. Whereas in adults the beneﬁt
of ATG (GVHD reduction) outweighs the risks (eg, viral in-
fections), this may not apply to children, who are less likely
to develop GVHD compared with adults (without serother-
apy) [1]. ATG has become a new standard in GVHD prophy-
laxis in the setting of adult myeloablative marrow or
mobilized blood stem cell transplantation. Investigations
into whether another form of in vivo T cell depletion (eg,
alemtuzumab) may be more advantageous than ATG should
use patients in whom the favorable risk to beneﬁt ratio of
ATG has been documented.ACKNOWLEDGMENTS
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